Company Overview
Grace Therapeutics, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it engages in the development and commercialization of pharmaceutical products designed for rare and orphan diseases in Canada. The company's operational scope includes the lead product candidate GTX-104, an intravenous infusion intended to treat subarachnoid hemorrhage, alongside the development of GTX-102, an oral mucosal spray. In terms of scale, the company carries a market capitalization of $70.86M and employs a small workforce of 6 individuals, while its annual revenue is not currently disclosed in the available data. The combination of a market cap of $70.86M with no disclosed revenue indicates that the company is in an early-stage biotechnology development phase, relying heavily on capital deployment for product advancement rather than current commercial sales. This valuation suggests the market prices the enterprise based on potential future milestones and pipeline assets rather than established cash-flow generation from existing operations.
Financial Health
Grace Therapeutics, Inc. reports a net income of $-5,979,000 and an EBITDA of $-11,241,000 over the trailing twelve-month period, while its revenue and price-to-sales figures are not available for disclosure. The significant gap between the reported net income of $-5,979,000 and the EBITDA of $-11,241,000 reveals a cost structure where interest and tax expenses, or potentially non-operating losses, are driving a substantial portion of the total economic loss beyond the core operational burn. The company generates a free cash flow of $-6,619,000, which indicates that the organization is currently burning cash to fund its research and development activities, thereby limiting its financial flexibility until successful commercialization or additional capital raising occurs. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the typical accounting treatment for early-stage biotechnology firms that have not yet generated significant sales volume to calculate meaningful percentage margins. Regarding liquidity and leverage, the company holds $18.67M in cash against a debt level that is not available for disclosure, resulting in a debt-to-equity ratio that is also not available, though the absence of reported debt suggests a conservative balance sheet approach rather than a leveraged one. The current ratio stands at 14.96, an exceptionally high figure that indicates robust short-term liquidity and a strong ability to cover short-term obligations with its current assets. Furthermore, the return on equity is -10.2% and the return on assets is -10.8%, metrics that reveal management is currently consuming equity and assets to fuel growth rather than generating returns, which is standard for pre-revenue life science companies.
Valuation Assessment
The valuation metrics for Grace Therapeutics, Inc. show a P/E ratio (TTM) that is not available and a forward P/E of -7.35, the difference between these figures implies that the market is not valuing the company based on current or near-term earnings but rather on asset value or potential future profitability once earnings turn positive. The price-to-book ratio is 1.11, indicating that the market values the company at a slight premium over its book value, which suggests investors are willing to pay a small amount above the net asset value for the company's intangible assets and pipeline potential. Since the price-to-sales ratio is not available and the EV/EBITDA is -4.77, these alternative valuation metrics suggest that traditional earnings-based multiples are inappropriate, and the valuation is instead anchored to the company's net asset position and cash reserves. Over the past year, the stock has ranged between a 52-week high of $4.91 and a 52-week low of $1.75, meaning the current price sits at a specific point within this range that reflects the volatility typical of small-cap biotechnology stocks. The beta value of 0.76 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings compared to high-beta equities, although this lower volatility does not necessarily correlate with lower risk given the company's lack of revenue.
Growth & Income
Grace Therapeutics, Inc. reports revenue growth and earnings growth rates that are both not available due to the lack of historical revenue data required to calculate year-over-year percentages, preventing a direct comparison of whether earnings are growing faster or slower than revenue. The company does not pay a dividend, as evidenced by a dividend yield that is not available and a payout ratio of 0.0%, which means the company reinvests all available earnings and cash reserves back into its research and development pipeline rather than distributing income to shareholders. The absence of a dividend yield and a payout ratio of 0.0% confirms that the company is in a growth phase where capital retention is prioritized over income distribution to external investors. Consequently, the overall growth and income profile for Grace Therapeutics, Inc. is characterized by a complete reliance on capital appreciation potential and pipeline progression, with no current income generation to support shareholder returns.